|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 255.32 USD | -1.44% |
|
-0.68% | +6.00% |
| 06/03 | Resmed Insider Sold Shares Worth $520,440, According to a Recent SEC Filing | MT |
| 04/03 | ASX Biggest Gainers | MT |
Company Valuation: ResMed, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 35,903 | 30,691 | 32,133 | 28,117 | 37,762 | 37,195 | - | - |
| Change | - | -14.52% | 4.7% | -12.5% | 34.31% | -1.5% | - | - |
| Enterprise Value (EV) 1 | 36,263 | 31,192 | 33,346 | 28,585 | 37,221 | 36,129 | 35,311 | 34,232 |
| Change | - | -13.98% | 6.9% | -14.28% | 30.21% | -2.93% | -2.26% | -3.06% |
| P/E ratio | 76.1x | 39.6x | 35.9x | 27.7x | 27.1x | 24.1x | 21.6x | 19.8x |
| PBR | 12.4x | 9.35x | 7.76x | 5.78x | 6.33x | 5.45x | 4.78x | 4.43x |
| PEG | - | 0.6x | 2.4x | 2x | 0.7x | 2.1x | 1.9x | 2.12x |
| Capitalization / Revenue | 11.2x | 8.58x | 7.61x | 6x | 7.34x | 6.59x | 6.13x | 5.73x |
| EV / Revenue | 11.3x | 8.72x | 7.9x | 6.1x | 7.23x | 6.4x | 5.82x | 5.27x |
| EV / EBITDA | 33.8x | 26.8x | 25.3x | 18.1x | 19.8x | 16.4x | 14.9x | 13.3x |
| EV / EBIT | 40.1x | 31.2x | 27.2x | 19.3x | 21.1x | 17.6x | 15.8x | 14.1x |
| EV / FCF | 57.2x | 144x | 58.1x | 22x | 22.4x | 23.7x | 21.1x | 19x |
| FCF Yield | 1.75% | 0.69% | 1.72% | 4.55% | 4.46% | 4.21% | 4.74% | 5.25% |
| Dividend per Share 2 | 1.56 | 1.68 | 1.8 | 1.92 | 2.12 | 2.434 | 2.696 | 2.635 |
| Rate of return | 0.63% | 0.8% | 0.82% | 1% | 0.82% | 0.95% | 1.06% | 1.03% |
| EPS 2 | 3.24 | 5.3 | 6.09 | 6.92 | 9.51 | 10.59 | 11.81 | 12.92 |
| Distribution rate | 48.1% | 31.7% | 29.6% | 27.7% | 22.3% | 23% | 22.8% | 20.4% |
| Net sales 1 | 3,197 | 3,578 | 4,223 | 4,685 | 5,146 | 5,645 | 6,069 | 6,494 |
| EBITDA 1 | 1,074 | 1,162 | 1,317 | 1,576 | 1,884 | 2,198 | 2,367 | 2,578 |
| EBIT 1 | 903.7 | 1,000 | 1,224 | 1,478 | 1,763 | 2,050 | 2,240 | 2,425 |
| Net income 1 | 474.5 | 779.4 | 897.6 | 1,021 | 1,401 | 1,543 | 1,727 | 1,890 |
| Net Debt 1 | 360.1 | 501.5 | 1,213 | 468.9 | -541.2 | -1,066 | -1,883 | -2,963 |
| Reference price 2 | 246.52 | 209.63 | 218.50 | 191.42 | 258.00 | 255.32 | 255.32 | 255.32 |
| Nbr of stocks (in thousands) | 145,640 | 146,405 | 147,062 | 146,884 | 146,365 | 145,678 | - | - |
| Announcement Date | 5/8/21 | 11/8/22 | 3/8/23 | 1/8/24 | 31/7/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 24.47x | 6.5x | 16.68x | 0.94% | 37.74B | ||
| 26.32x | 4.61x | 18.01x | 0.36% | 190B | ||
| 56.72x | 14.7x | 34.21x | -.--% | 178B | ||
| 31.99x | 6.04x | 18.92x | 0.65% | 145B | ||
| 29.49x | 5.06x | 16.37x | -.--% | 107B | ||
| 20.88x | 2.42x | 12.02x | 2.53% | 53.73B | ||
| 29.57x | 6.74x | 21.66x | -.--% | 49.5B | ||
| 16.35x | 1.85x | 10x | 0.21% | 36.01B | ||
| 23.12x | 4.74x | 16.41x | 0.85% | 34.06B | ||
| 26.95x | 5.56x | 17.43x | -.--% | 31.3B | ||
| Average | 28.59x | 5.82x | 18.17x | 0.55% | 86.27B | |
| Weighted average by Cap. | 33.18x | 6.98x | 20.66x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- RMD Stock
- Valuation ResMed, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















